Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 13
Submit an article Journal homepage
181
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma

Eleftheria LamprianidouDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece; View further author information
,
Emmanouela ZouliaDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece; View further author information
,
Elsa BernardCenter for Molecular Oncology, Center for Heme Malignancies and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Chryssoula KordellaDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece; View further author information
,
Menelaos PapoutselisDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece; View further author information
,
Zoi BezirgiannidouDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece; View further author information
,
George VrachioliasDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece; View further author information
,
Elli PapaemmanuilCenter for Molecular Oncology, Center for Heme Malignancies and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
&
Ioannis KotsianidisDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece; Correspondence[email protected]
View further author information
 show all
Pages 3277-3281 | Received 25 Feb 2019, Accepted 30 May 2019, Published online: 12 Jun 2019

References

  • Stresemann C, Bokelmann I, Mahlknecht U, et al. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 2008;7:2998–3005.
  • Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014;99:613–619.
  • Valencia A, Masala E, Rossi A, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014;28:621–628.
  • Unnikrishnan A, Papaemmanuil E, Beck D, et al. Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017;20:572–585.
  • Agrawal K, Das V, Vyas P, et al. Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic. Pharmacol Ther. 2018;188:45–79.
  • Jabbour EJ, Garcia-Manero G, Strati P, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015;121:876–882.
  • Prebet T, Thepot S, Gore SD, et al. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica. 2013;98:e18–19.
  • Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–3627.
  • Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124:1513–1521.
  • Park S, Hamel JF, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. Jco. 2017;35:1591–1597.
  • Guo Y, Zhou Y, Yamatomo S, et al. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019;33:1287–1291.
  • Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007;21:505–510.
  • Perez C, Pascual M, Martin-Subero JI, et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2013;98:1414–1420.
  • Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008;22:965–970.
  • Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015;125:499–503.
  • Lasho TL, Finke CM, Zblewski D, et al. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer J. 2015;5:e275.
  • Kuendgen A, Muller-Thomas C, Lauseker M, et al. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget. 2018;9:27882–27894.
  • Merlevede J, Droin N, Qin T, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.
  • Meldi K, Qin T, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015;125:1857–1872.
  • Nazha A, Komrokji RS, Garcia-Manero G, et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016;101:e224–227.
  • Leung KK, Nguyen A, Shi T, et al. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome. Proc Natl Acad Sci USA. 2019;116:695–700.
  • Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013;121:1633–1643.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.